Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer.

Trial Profile

Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Carcinoembryonic antigen DNA vaccine (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor; Granulocyte macrophage colony stimulating factor
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms El-porCEA
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 Mar 2012 Last checked against European Clinical Trials Database record.
    • 27 Feb 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top